Bristol Myers Squibb has axed the degrader-antibody conjugate (DAC) it bought from Orum Therapeutics for $100 million, ...
The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate ...
Electra Therapeutics is the latest biotech to overshoot its own IPO expectations this year, with the inflammation-focused company bringing in $350 million from this morning’s Nasdaq listing. | Electra ...
Artelo Biosciences’ oral dual cannabinoid agonist showed weight loss comparable to the GLP-1 receptor agonist semaglutide in obese mice. | Artelo Biosciences’ oral dual cannabinoid agonist showed ...
New-look Novo is digging deeper into its metabolic roots with three new obesity programs purchased from New York biotech Kallyope. | New-look Novo is digging deeper into its metabolic roots with three ...
The FDA cleared Medtronic’s LigSure RAS Maryland jaw vessel sealer-divider to be used in combination with the device maker’s Hugo robotic-assisted surgery system. The device is geared toward providing ...
The FDA granted Aptitude its first 510(k) clearance for the next-generation Metrix COVID diagnostic that features three-times greater sensitivity with 30% faster results that its original emergency ...
Prediction markets are opening up new ways to bet on biopharma events, from clinical trial readouts to FDA approvals. | In this episode of “The Top Line,” we explore the growing space of biopharma ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
After decades of hard-won progress, ALS drug development is entering a new era, building on established efficacy measures like survival and ALSFRS-R with biology-driven science that captures the full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results